Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 3/20 | 0.32 |
| ▸ | PPARD | Q03181 | 3/20 | 0.32 |
| ▸ | PPARA | Q07869 | 3/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | GALK1 | P51570 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519838 | 0.89 | TP53 (0.39) | TP53MAPTRORCALDH1A1L3MBTL1 | |
| SCHEMBL12096759 | 0.86 | PPARG (0.43) | TP53MAPTRORCPPARGPPARD | |
| SCHEMBL14054102 | 0.84 | MAPT (0.40) | TP53MAPTRORCALDH1A1L3MBTL1 | |
| SCHEMBL14054794 | 0.83 | TP53 (0.35) | TP53MAPTRORCALDH1A1L3MBTL1 | |
| SCHEMBL14053991 | 0.82 | TP53 (0.38) | TP53MAPTRORCALDH1A1L3MBTL1 | |
| SCHEMBL12096942 | 0.80 | PPARG (0.44) | TP53MAPTRORCPPARGPPARD | |
| SCHEMBL15519846 | 0.79 | TP53 (0.41) | TP53MAPTRORCALDH1A1L3MBTL1 | |
| SCHEMBL18299930 | 0.77 | TP53 (0.36) | TP53MAPTRORCALDH1A1PPARG | |
| SCHEMBL15519752 | 0.77 | MAPT (0.38) | TP53MAPTRORCALDH1A1L3MBTL1 | |
| SCHEMBL14053482 | 0.74 | TP53 (0.42) | TP53MAPTRORCALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521727-B1 | NEW BENZOIC PYRROLOPYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PARKINSON'S DISEASE | INVENTIVA (FR) | 2014-03-19 | — | — | EP | claimed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | claimed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | claimed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | disclosed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | disclosed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | NCOR1, NCOR2, NR0B1 | TP53 2199/4885MAPT 3895/4885RORC 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.